EyePoint Pharmaceuticals Analyst Ratings
EyePoint Pharmaceuticals Analyst Ratings
EyePoint Pharmaceuticals Analyst Ratings
JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Phase 3 Trials and FDA Alignment
EyePoint Pharmaceuticals Analyst Ratings
EyePoint Pharmaceuticals: Maintaining Buy Rating Amidst Progress and Trials
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Positive Duravyu Trial Insights and Future Prospects
Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating
EyePoint Pharmaceuticals Analyst Ratings
Baird Maintains Outperform on EyePoint Pharmaceuticals, Lowers Price Target to $38
Maintaining Buy Rating on EyePoint Pharmaceuticals Despite P2 Study Setback
EyePoint Pharmaceuticals Analyst Ratings
Maintaining Buy Rating on EyePoint Pharmaceuticals: Strong Prospects in WAMD Market Despite NPDR Study Setback
Bullish Buy Rating Reaffirmed for EyePoint Pharmaceuticals With a $39 Price Target
EyePoint Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Maintains $33 Price Target
Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Clinical Trials and Market Expansion Potential
Analysts Are Bullish on Top Healthcare Stocks: Oxford BioMedica (OXBDF), EyePoint Pharmaceuticals (EYPT)
EyePoint Pharmaceuticals: Strategic Leadership Appointment and Positive Developments Bolster Buy Rating